학술논문
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
Document Type
Article
Author
Phillips, Richard O; Robert, Jérôme; Abass, Kabiru Mohamed; Thompson, William; Sarfo, Fred Stephen; Wilson, Tuah; Sarpong, Godfred; Gateau, Thierry; Chauty, Annick; Omollo, Raymond; Ochieng Otieno, Michael; Egondi, Thaddaeus W; Ampadu, Edwin O; Agossadou, Didier; Marion, Estelle; Ganlonon, Line; Wansbrough-Jones, Mark; Grosset, Jacques; Macdonald, John M; Treadwell, Terry; Saunderson, Paul; Paintsil, Albert; Lehman, Linda; Frimpong, Michael; Sarpong, Nanaa Francisca; Saizonou, Raoul; Tiendrebeogo, Alexandre; Ohene, Sally-Ann; Stienstra, Ymkje; Asiedu, Kingsley B; van der Werf, Tjip S; Osei Mireku, Samuel; Abotsi, Justice; Adu Poku, Joseph Ken; Asamoah-Frimpong, Richard; Osei-Wusu, Bright; Sarpong, Edward; Konadu, Beatrice; Opoku, Ernest; Forson, Mark; Ndogyele, Mathias; Ofori, Elizabeth; Aboagye, Felicity; Berko, Thomas; Amofa, George; Nsiah, Anastasia; Mensah-Bonsu, Joyce; Ofori Nyarko, Joseph; Amoako, Yaw Ampem; Koranteng Tannor, Elliot; Boakye-Appiah, Justice; Dzibordzi Loglo, Aloysius; Sarpong-Duah, Mabel; Agbavor, Bernadette; Ardent, Marie Françoise; Yamadjako, Arnaud; Adanmado Gersande, Naomi; Adeye, Ambroise; Kindjinou, Martial; Akpolan; Kiki, Maxime; Sodjinou, Espoir; Guegnard, Clémence; Klis, Sandor-Adrian; Velding, Kristien; Omansen, Till; Ofori-Adjei, David; Eyangoh, Sarah; Knell, Alan; Faber, William
Source
The Lancet; April 2020, Vol. 395 Issue: 10232 p1259-1267, 9p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulceransinfection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions.